Amgen's Evolocumab slashes "bad" cholesterol by up to 66% in trial

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen's (AMGN) Evolocumab cut "bad" LDL cholesterol by 55-66% vs a placebo in three Phase III trials. The drug also didn't show any serious safety problems.

Amgen presented the data yesterday, fleshing out an earlier disclosure that the drug had achieved its main targets in five late-stage trials of 4,000 patients. Amgen is set to present data from the other two studies today.

Evolocumab is part of a new class of drugs called PCSK9 inhibitors, which block a protein that inhibits the ability of the liver to remove LDL from the blood.

Analysts have forecast that annual sales of each such drug could hit $3B or more. (PR)